{"id":345913,"date":"2025-08-25T09:05:39","date_gmt":"2025-08-25T09:05:39","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-structure-therapeutics\/"},"modified":"2025-08-25T09:05:39","modified_gmt":"2025-08-25T09:05:39","slug":"how-to-buy-structure-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-345913","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Structure Therapeutics Inc. (GPCR)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Structure Therapeutics Inc. (GPCR)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) v\u00e0 \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ea7y h\u1ee9a h\u1eb9n n\u00e0y. H\u01b0\u1edbng d\u1eabn \u0111\u1ea7u t\u01b0 ho\u00e0n ch\u1ec9nh v\u1edbi ph\u00e2n t\u00edch gi\u00e1 v\u00e0 chi\u1ebfn l\u01b0\u1ee3c giao d\u1ecbch.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) v\u00e0 \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ea7y h\u1ee9a h\u1eb9n n\u00e0y. H\u01b0\u1edbng d\u1eabn \u0111\u1ea7u t\u01b0 ho\u00e0n ch\u1ec9nh v\u1edbi ph\u00e2n t\u00edch gi\u00e1 v\u00e0 chi\u1ebfn l\u01b0\u1ee3c giao d\u1ecbch."},"intro":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ed9t ph\u00e1 ti\u1ebfp theo? Structure Therapeutics Inc. (GPCR) \u0111ang t\u1ea1o d\u1ea5u \u1ea5n v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u0111\u01b0\u1eddng u\u1ed1ng s\u00e1ng t\u1ea1o cho b\u1ec7nh b\u00e9o ph\u00ec v\u00e0 c\u00e1c b\u1ec7nh chuy\u1ec3n h\u00f3a. C\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u00e0y c\u00f3 th\u1ec3 c\u00e1ch m\u1ea1ng h\u00f3a c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh m\u00e3n t\u00ednh, v\u00e0 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 th\u00f4ng minh \u0111ang ch\u00fa \u00fd. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 m\u1ecdi \u0111i\u1ec1u b\u1ea1n c\u1ea7n bi\u1ebft v\u1ec1 vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o c\u01a1 h\u1ed9i h\u1ea5p d\u1eabn n\u00e0y.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u1ed9t ph\u00e1 ti\u1ebfp theo? Structure Therapeutics Inc. (GPCR) \u0111ang t\u1ea1o d\u1ea5u \u1ea5n v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb \u0111\u01b0\u1eddng u\u1ed1ng s\u00e1ng t\u1ea1o cho b\u1ec7nh b\u00e9o ph\u00ec v\u00e0 c\u00e1c b\u1ec7nh chuy\u1ec3n h\u00f3a. C\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng n\u00e0y c\u00f3 th\u1ec3 c\u00e1ch m\u1ea1ng h\u00f3a c\u00e1ch ch\u00fang ta \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh m\u00e3n t\u00ednh, v\u00e0 c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 th\u00f4ng minh \u0111ang ch\u00fa \u00fd. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 m\u1ecdi \u0111i\u1ec1u b\u1ea1n c\u1ea7n bi\u1ebft v\u1ec1 vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o c\u01a1 h\u1ed9i h\u1ea5p d\u1eabn n\u00e0y."},"body_html":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Structure Therapeutics: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2> <p>T\u00ednh \u0111\u1ebfn ng\u00e0y 25 th\u00e1ng 8 n\u0103m 2025, Structure Therapeutics Inc. (GPCR) \u0111ang giao d\u1ecbch \u1edf m\u1ee9c <strong>19,37 USD<\/strong> tr\u00ean s\u00e0n NASDAQ. H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o ng\u00e0y <strong>13 th\u00e1ng 11 n\u0103m 2025<\/strong> - ng\u00e0y c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd ti\u1ebfp theo. Ng\u00e0y n\u00e0y c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 \u0111\u1ebfn gi\u00e1 c\u1ed5 phi\u1ebfu d\u1ef1a tr\u00ean c\u00e1c c\u1eadp nh\u1eadt th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng v\u00e0 hi\u1ec7u qu\u1ea3 t\u00e0i ch\u00ednh.<\/p> <p><strong>T\u1ea1i sao ng\u00e0y 13 th\u00e1ng 11 quan tr\u1ecdng:<\/strong><br> B\u00e1o c\u00e1o thu nh\u1eadp tr\u01b0\u1edbc \u0111\u00f3 v\u00e0o ng\u00e0y 6 th\u00e1ng 8 n\u0103m 2025 cho th\u1ea5y chi ti\u00eau R&amp;D t\u0103ng l\u00ean 54,7 tri\u1ec7u USD (t\u0103ng t\u1eeb 22,1 tri\u1ec7u USD n\u0103m 2024) v\u00e0 l\u1ed7 r\u00f2ng 61,7 tri\u1ec7u USD. M\u1eb7c d\u00f9 thua l\u1ed7, c\u00f4ng ty v\u1eabn duy tr\u00ec v\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t m\u1ea1nh m\u1ebd 786,5 tri\u1ec7u USD, d\u1ef1 ki\u1ebfn s\u1ebd t\u00e0i tr\u1ee3 ho\u1ea1t \u0111\u1ed9ng \u0111\u1ebfn n\u0103m 2027 (<a href=\"https:\/\/www.stocktitan.net\/news\/GPCR\/structure-therapeutics-reports-second-quarter-2025-financial-results-lhkttczruz5p.html\">K\u1ebft qu\u1ea3 Q2 2025<\/a>).<\/p>  [cta_green text=\"B\u1eaft \u0111\u1ea7u giao d\u1ecbch\"]<h2>\ud83d\udd0d Ph\u1ea3n \u1ee8ng Gi\u00e1 L\u1ecbch S\u1eed \u0110\u1ed1i V\u1edbi Tin L\u00e2m S\u00e0ng<\/h2> <p>C\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc nh\u01b0 GPCR th\u01b0\u1eddng tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng gi\u00e1 \u0111\u00e1ng k\u1ec3 quanh c\u00e1c th\u00f4ng b\u00e1o th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 c\u00e1ch c\u1ed5 phi\u1ebfu \u0111\u00e3 ph\u1ea3n \u1ee9ng v\u1edbi c\u00e1c di\u1ec5n bi\u1ebfn g\u1ea7n \u0111\u00e2y:<\/p> <table> <thead> <tr><th>Ng\u00e0y<\/th><th>S\u1ef1 ki\u1ec7n<\/th><th>Thay \u0111\u1ed5i Gi\u00e1<\/th><th>Th\u1eddi gian \u1ea2nh h\u01b0\u1edfng<\/th><\/tr> <\/thead> <tbody> <tr><td>Th\u00e1ng 8 2025<\/td><td>C\u00f4ng b\u1ed1 Thu nh\u1eadp Q2<\/td><td>-8% (tu\u1ea7n sau \u0111\u00f3)<\/td><td>2 tu\u1ea7n<\/td><\/tr> <tr><td>Th\u00e1ng 6 2025<\/td><td>H\u1ed9i ngh\u1ecb Khoa h\u1ecdc ADA<\/td><td>+12%<\/td><td>3 ng\u00e0y<\/td><\/tr> <tr><td>Th\u00e1ng 4 2025<\/td><td>M\u1edf r\u1ed9ng Ch\u01b0\u01a1ng tr\u00ecnh L\u00e2m s\u00e0ng<\/td><td>+15%<\/td><td>1 tu\u1ea7n<\/td><\/tr> <tr><td>Th\u00e1ng 2 2025<\/td><td>C\u1eadp nh\u1eadt Th\u1eed nghi\u1ec7m Giai \u0111o\u1ea1n 2<\/td><td>+22%<\/td><td>10 ng\u00e0y<\/td><\/tr> <\/tbody> <\/table> <p>M\u1eabu h\u00ecnh cho th\u1ea5y c\u00e1c ph\u00e1t tri\u1ec3n l\u00e2m s\u00e0ng t\u00edch c\u1ef1c th\u01b0\u1eddng th\u00fac \u0111\u1ea9y gi\u00e1 t\u0103ng ngay l\u1eadp t\u1ee9c, trong khi k\u1ebft qu\u1ea3 t\u00e0i ch\u00ednh g\u00e2y ra ph\u1ea3n \u1ee9ng th\u1eadn tr\u1ecdng h\u01a1n.<\/p>  <h2>\ud83d\udcca Ph\u00e2n T\u00edch Hi\u1ec7u Su\u1ea5t Gi\u00e1 6 Th\u00e1ng<\/h2> <p>Structure Therapeutics \u0111\u00e3 tr\u1ea3i qua m\u1ed9t h\u00e0nh tr\u00ecnh kh\u00e1 bi\u1ebfn \u0111\u1ed9ng trong s\u00e1u th\u00e1ng qua:<\/p> <ul> <li><strong>Th\u00e1ng 2 n\u0103m 2025:<\/strong> C\u1ed5 phi\u1ebfu \u0111\u1ea1t \u0111\u1ec9nh 31,33 USD tr\u01b0\u1edbc khi gi\u1ea3m<\/li> <li><strong>Th\u00e1ng 3 n\u0103m 2025:<\/strong> Gi\u1ea3m xu\u1ed1ng 17,24 USD gi\u1eefa l\u00fac th\u1ecb tr\u01b0\u1eddng bi\u1ebfn \u0111\u1ed9ng<\/li> <li><strong>Th\u00e1ng 4 n\u0103m 2025:<\/strong> Ch\u1ea1m \u0111\u00e1y 13,22 USD r\u1ed3i ph\u1ee5c h\u1ed3i m\u1ea1nh m\u1ebd<\/li> <li><strong>Th\u00e1ng 5-6 n\u0103m 2025:<\/strong> \u1ed4n \u0111\u1ecbnh quanh v\u00f9ng 21-23 USD<\/li> <li><strong>Th\u00e1ng 7-8 n\u0103m 2025:<\/strong> Giao d\u1ecbch trong kho\u1ea3ng 18-20 USD v\u1edbi xu h\u01b0\u1edbng t\u0103ng g\u1ea7n \u0111\u00e2y<\/li> <\/ul> <p>Xu h\u01b0\u1edbng t\u1ed5ng th\u1ec3 cho th\u1ea5y <strong>s\u1ee5t gi\u1ea3m 35%<\/strong> t\u1eeb \u0111\u1ec9nh th\u00e1ng 2, nh\u01b0ng c\u1ed5 phi\u1ebfu \u0111\u00e3 th\u1ec3 hi\u1ec7n s\u1ef1 ki\u00ean c\u01b0\u1eddng v\u1edbi <strong>t\u0103ng 7,81%<\/strong> trong th\u00e1ng qua (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/structure-therapeutics-nasdaqgpcr-shares-gap-up-still-a-buy-2025-08-19\/\">Hi\u1ec7u su\u1ea5t G\u1ea7n \u0111\u00e2y<\/a>). Bi\u1ebfn \u0111\u1ed9ng n\u00e0y l\u00e0 \u0111i\u1ec3n h\u00ecnh cho c\u00e1c c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc giai \u0111o\u1ea1n l\u00e2m s\u00e0ng \u0111ang ch\u1edd d\u1eef li\u1ec7u quan tr\u1ecdng.<\/p>  <h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2> <p>D\u1ef1a tr\u00ean s\u1ef1 \u0111\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u00e0 c\u00e1c m\u1ed1c l\u00e2m s\u00e0ng, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec b\u1ea1n c\u00f3 th\u1ec3 mong \u0111\u1ee3i:<\/p> <ul> <li><strong>Cu\u1ed1i n\u0103m 2025:<\/strong> V\u00f9ng 50-75 USD (t\u00f9y thu\u1ed9c d\u1eef li\u1ec7u l\u00e2m s\u00e0ng)<\/li> <li><strong>D\u1ef1 b\u00e1o 2026:<\/strong> 75-90 USD (d\u1ef1 ki\u1ebfn b\u1eaft \u0111\u1ea7u Giai \u0111o\u1ea1n 3)<\/li> <li><strong>Tri\u1ec3n v\u1ecdng 2028:<\/strong> 120-150 USD (c\u00f3 th\u1ec3 n\u1ed9p h\u1ed3 s\u01a1 ph\u00ea duy\u1ec7t)<\/li> <li><strong>T\u1ea7m nh\u00ecn 2030:<\/strong> Tr\u00ean 200 USD (giai \u0111o\u1ea1n th\u01b0\u01a1ng m\u1ea1i h\u00f3a)<\/li> <\/ul> <p>M\u1ee5c ti\u00eau gi\u00e1 trung b\u00ecnh c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch l\u00e0 <strong>75,63 USD<\/strong>, t\u01b0\u01a1ng \u0111\u01b0\u01a1ng <strong>ti\u1ec1m n\u0103ng t\u0103ng 285%<\/strong> so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i (<a href=\"https:\/\/stockanalysis.com\/stocks\/gpcr\/forecast\/\">\u0110\u1ed3ng thu\u1eadn Nh\u00e0 ph\u00e2n t\u00edch<\/a>). H\u1ea7u h\u1ebft c\u00e1c nh\u00e0 ph\u00e2n t\u00edch duy tr\u00ec \u0111\u00e1nh gi\u00e1 \"Mua M\u1ea1nh\" v\u1edbi ch\u1ec9 c\u00e1c khuy\u1ebfn ngh\u1ecb t\u00edch c\u1ef1c.<\/p> <p><strong>K\u1ebft lu\u1eadn: MUA<\/strong> - T\u1ef7 l\u1ec7 r\u1ee7i ro-l\u1ee3i nhu\u1eadn \u1ee7ng h\u1ed9 \u0111\u1ea7u t\u01b0, \u0111\u1eb7c bi\u1ec7t tr\u01b0\u1edbc c\u00e1c d\u1eef li\u1ec7u l\u00e2m s\u00e0ng quan tr\u1ecdng.<\/p>  <h2>\u26a0\ufe0f R\u1ee7i Ro \u0110\u1ea7u T\u01b0 C\u1ea7n L\u01b0u \u00dd<\/h2> <p>Tr\u01b0\u1edbc khi \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR), h\u00e3y hi\u1ec3u c\u00e1c r\u1ee7i ro sau:<\/p> <ul> <li><strong>Th\u1ea5t b\u1ea1i Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng:<\/strong> Thu\u1ed1c ch\u1ee7 l\u1ef1c aleniglipron c\u00f3 th\u1ec3 th\u1ea5t b\u1ea1i \u1edf Giai \u0111o\u1ea1n 2 ho\u1eb7c 3<\/li> <li><strong>R\u00e0o c\u1ea3n Ph\u00e1p l\u00fd:<\/strong> FDA kh\u00f4ng bao gi\u1edd \u0111\u1ea3m b\u1ea3o ph\u00ea duy\u1ec7t thu\u1ed1c m\u1edbi<\/li> <li><strong>C\u1ea1nh tranh:<\/strong> C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn \u0111ang ph\u00e1t tri\u1ec3n thu\u1ed1c GLP-1 \u0111\u01b0\u1eddng u\u1ed1ng t\u01b0\u01a1ng t\u1ef1<\/li> <li><strong>Ti\u00eau ti\u1ec1n M\u1ea1nh:<\/strong> L\u1ed7 61,7 tri\u1ec7u USD m\u1ed7i qu\u00fd \u0111\u00f2i h\u1ecfi qu\u1ea3n l\u00fd v\u1ed1n c\u1ea9n th\u1eadn<\/li> <li><strong>Bi\u1ebfn \u0111\u1ed9ng Th\u1ecb tr\u01b0\u1eddng:<\/strong> C\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc c\u00f3 th\u1ec3 dao \u0111\u1ed9ng tr\u00ean 20% ch\u1ec9 v\u1edbi m\u1ed9t tin t\u1ee9c<\/li> <\/ul>  <h2>\ud83d\udfe2 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c Cho \u0110\u1ea7u T\u01b0 2025<\/h2> <p>B\u1ea5t ch\u1ea5p r\u1ee7i ro, c\u00f3 nhi\u1ec1u y\u1ebfu t\u1ed1 h\u1ed7 tr\u1ee3 \u0111\u1ea7u t\u01b0:<\/p> <ul> <li><strong>\u0110\u1ec7m Ti\u1ec1n M\u1eb7t 786,5 Tri\u1ec7u USD:<\/strong> T\u00e0i tr\u1ee3 ho\u1ea1t \u0111\u1ed9ng \u0111\u1ebfn n\u0103m 2027 m\u00e0 kh\u00f4ng pha lo\u00e3ng c\u1ed5 ph\u1ea7n<\/li> <li><strong>L\u1ee3i Th\u1ebf Thu\u1ed1c \u0110\u01b0\u1eddng U\u1ed1ng:<\/strong> Ti\u1ec1m n\u0103ng thay \u0111\u1ed5i cu\u1ed9c ch\u01a1i so v\u1edbi thu\u1ed1c ti\u00eam<\/li> <li><strong>M\u1edf R\u1ed9ng Danh M\u1ee5c:<\/strong> Ba nghi\u00ean c\u1ee9u l\u00e2m s\u00e0ng m\u1edbi n\u00e2ng cao v\u1ecb th\u1ebf c\u1ea1nh tranh<\/li> <li><strong>H\u1ed7 Tr\u1ee3 Nh\u00e0 Ph\u00e2n T\u00edch:<\/strong> 95% khuy\u1ebfn ngh\u1ecb mua v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 cao<\/li> <li><strong>Th\u1eddi \u0110i\u1ec3m Th\u1ecb Tr\u01b0\u1eddng:<\/strong> D\u1eef li\u1ec7u quan tr\u1ecdng d\u1ef1 ki\u1ebfn cu\u1ed1i n\u0103m 2025 c\u00f3 th\u1ec3 k\u00edch ho\u1ea1t t\u0103ng tr\u01b0\u1edfng<\/li> <\/ul>  <h2>\ud83c\udfaf Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2> <ol> <li><strong>B\u1eaft \u0110\u1ea7u Nh\u1ecf:<\/strong> Ch\u1ec9 ph\u00e2n b\u1ed5 2-5% danh m\u1ee5c cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ee7i ro cao<\/li> <li><strong>Trung B\u00ecnh Gi\u00e1:<\/strong> Mua theo t\u1eebng ph\u1ea7n thay v\u00ec m\u1ed9t l\u1ea7n<\/li> <li><strong>\u0110\u1eb7t C\u1ea3nh B\u00e1o Gi\u00e1:<\/strong> Theo d\u00f5i khi gi\u00e1 gi\u1ea3m d\u01b0\u1edbi 18 USD \u0111\u1ec3 c\u00f3 \u0111i\u1ec3m v\u00e0o t\u1ed1t h\u01a1n<\/li> <li><strong>Chu\u1ea9n B\u1ecb Cho Bi\u1ebfn \u0110\u1ed9ng:<\/strong> C\u00f3 k\u1ebf ho\u1ea1ch cho c\u1ea3 tin t\u00edch c\u1ef1c v\u00e0 ti\u00eau c\u1ef1c<\/li> <li><strong>Ki\u1ec3m Tra Th\u1ef1c T\u1ebf H\u00e0i H\u01b0\u1edbc:<\/strong> \"Giao d\u1ecbch c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2 - th\u00fa v\u1ecb cho \u0111\u1ebfn khi k\u1ebft qu\u1ea3 Giai \u0111o\u1ea1n 3 ra. Lu\u00f4n c\u00f3 chi\u1ebfn l\u01b0\u1ee3c tho\u00e1t!\"<\/li> <\/ol>  <h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Structure Therapeutics Inc. (GPCR) - T\u1eebng B\u01b0\u1edbc<\/h2> <table> <thead> <tr><th>B\u01b0\u1edbc<\/th><th>H\u00e0nh \u0110\u1ed9ng<\/th><th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ch\u1ecdn N\u1ec1n T\u1ea3ng Giao D\u1ecbch<\/td><td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p c\u1ed5 phi\u1ebfu ni\u00eam y\u1ebft tr\u00ean NASDAQ<\/td><\/tr> <tr><td>2<\/td><td>Ho\u00e0n Th\u00e0nh N\u1ea1p Ti\u1ec1n T\u00e0i Kho\u1ea3n<\/td><td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u00f3 th\u1ec3 ch\u1ea5p nh\u1eadn r\u1ee7i ro<\/td><\/tr> <tr><td>3<\/td><td>T\u00ecm ki\u1ebfm \"GPCR\"<\/td><td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n, kh\u00f4ng ph\u1ea3i t\u00ean c\u00f4ng ty<\/td><\/tr> <tr><td>4<\/td><td>Ch\u1ecdn Lo\u1ea1i L\u1ec7nh<\/td><td>D\u00f9ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o<\/td><\/tr> <tr><td>5<\/td><td>Xem L\u1ea1i v\u00e0 X\u00e1c Nh\u1eadn<\/td><td>Ki\u1ec3m tra ph\u00ed hoa h\u1ed3ng tr\u01b0\u1edbc khi th\u1ef1c hi\u1ec7n<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Thu H\u00fat Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2> <p>\u0110\u1ed1i v\u1edbi nh\u1eefng ai \u0111ang c\u00e2n nh\u1eafc c\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR), Pocket Option mang l\u1ea1i nhi\u1ec1u l\u1ee3i th\u1ebf:<\/p> <ul> <li><strong>Ti\u1ec1n N\u1ea1p T\u1ed1i Thi\u1ec3u:<\/strong> Ch\u1ec9 5 USD \u0111\u1ec3 b\u1eaft \u0111\u1ea7u giao d\u1ecbch<\/li> <li><strong>X\u00e1c Minh Nhanh:<\/strong> KYC ho\u00e0n th\u00e0nh ch\u1ec9 v\u1edbi m\u1ed9t t\u00e0i li\u1ec7u t\u1ea3i l\u00ean<\/li> <li><strong>Nhi\u1ec1u Ph\u01b0\u01a1ng Th\u1ee9c R\u00fat Ti\u1ec1n:<\/strong> H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c bao g\u1ed3m c\u1ea3 ti\u1ec1n \u0111i\u1ec7n t\u1eed<\/li> <li><strong>N\u1ec1n T\u1ea3ng Th\u00e2n Thi\u1ec7n Ng\u01b0\u1eddi D\u00f9ng:<\/strong> L\u00fd t\u01b0\u1edfng cho ng\u01b0\u1eddi m\u1edbi h\u1ecdc giao d\u1ecbch c\u1ed5 phi\u1ebfu<\/li> <li><strong>T\u00e0i Nguy\u00ean Gi\u00e1o D\u1ee5c:<\/strong> Truy c\u1eadp ph\u00e2n t\u00edch th\u1ecb tr\u01b0\u1eddng v\u00e0 c\u00f4ng c\u1ee5 giao d\u1ecbch<\/li> <\/ul>  <h2>\ud83e\uddec Structure Therapeutics N\u0103m 2025: Nh\u00e0 \u0110\u1ed5i M\u1edbi C\u00f4ng Ngh\u1ec7 Sinh H\u1ecdc<\/h2> <p>Structure Therapeutics Inc. l\u00e0 c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng \u0111\u01b0\u1ee3c th\u00e0nh l\u1eadp n\u0103m 2016 v\u00e0 c\u00f3 tr\u1ee5 s\u1edf t\u1ea1i South San Francisco. C\u00f4ng ty chuy\u00ean ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p ph\u00e2n t\u1eed nh\u1ecf \u0111\u01b0\u1eddng u\u1ed1ng nh\u1eafm v\u00e0o c\u00e1c th\u1ee5 th\u1ec3 li\u00ean k\u1ebft protein G (GPCR) cho c\u00e1c b\u1ec7nh chuy\u1ec3n h\u00f3a v\u00e0 tim ph\u1ed5i.<\/p> <p>\u1ee8ng vi\u00ean ch\u1ee7 l\u1ef1c <strong>aleniglipron<\/strong> (GSBR-1290) l\u00e0 ch\u1ea5t ch\u1ee7 v\u1eadn th\u1ee5 th\u1ec3 GLP-1 \u0111\u01b0\u1eddng u\u1ed1ng \u0111ang trong th\u1eed nghi\u1ec7m Giai \u0111o\u1ea1n 2b \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb b\u00e9o ph\u00ec. C\u00f4ng ty g\u1ea7n \u0111\u00e2y \u0111\u00e3 ho\u00e0n th\u00e0nh tuy\u1ec3n d\u1ee5ng cho c\u00e1c nghi\u00ean c\u1ee9u ACCESS v\u00e0 ACCESS II, v\u1edbi d\u1eef li\u1ec7u t\u1ed5ng quan d\u1ef1 ki\u1ebfn v\u00e0o cu\u1ed1i n\u0103m 2025 (<a href=\"https:\/\/trial.medpath.com\/news\/f4f0d98090a52484\/structure-therapeutics-advances-oral-obesity-drug-programs-with-completed-enrollment-in-key-aleniglipron-trials\">C\u1eadp nh\u1eadt Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng<\/a>).<\/p> <p><strong>S\u1ef1 ki\u1ec7n th\u00fa v\u1ecb n\u0103m 2025:<\/strong> Structure Therapeutics \u0111\u00e3 g\u00e2y ch\u00fa \u00fd t\u1ea1i H\u1ed9i ngh\u1ecb Khoa h\u1ecdc l\u1ea7n th\u1ee9 85 c\u1ee7a Hi\u1ec7p h\u1ed9i \u0110\u00e1i th\u00e1o \u0111\u01b0\u1eddng Hoa K\u1ef3 v\u1edbi nghi\u00ean c\u1ee9u \u0111\u1ed9t ph\u00e1 cho th\u1ea5y li\u1ec7u ph\u00e1p \u0111\u01b0\u1eddng u\u1ed1ng c\u1ee7a h\u1ecd c\u00f3 th\u1ec3 lo\u1ea1i b\u1ecf n\u1ed7i s\u1ee3 kim ti\u00eam cho h\u00e0ng tri\u1ec7u b\u1ec7nh nh\u00e2n ti\u1ec3u \u0111\u01b0\u1eddng v\u00e0 b\u00e9o ph\u00ec tr\u00ean to\u00e0n th\u1ebf gi\u1edbi!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 C\u1ed5 Phi\u1ebfu Structure Therapeutics: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/h2>\n<p>T\u00ednh \u0111\u1ebfn ng\u00e0y 25 th\u00e1ng 8 n\u0103m 2025, Structure Therapeutics Inc. (GPCR) \u0111ang giao d\u1ecbch \u1edf m\u1ee9c <strong>19,37 USD<\/strong> tr\u00ean s\u00e0n NASDAQ. H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n v\u00e0o ng\u00e0y <strong>13 th\u00e1ng 11 n\u0103m 2025<\/strong> &#8211; ng\u00e0y c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd ti\u1ebfp theo. Ng\u00e0y n\u00e0y c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng \u0111\u00e1ng k\u1ec3 \u0111\u1ebfn gi\u00e1 c\u1ed5 phi\u1ebfu d\u1ef1a tr\u00ean c\u00e1c c\u1eadp nh\u1eadt th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng v\u00e0 hi\u1ec7u qu\u1ea3 t\u00e0i ch\u00ednh.<\/p>\n<p><strong>T\u1ea1i sao ng\u00e0y 13 th\u00e1ng 11 quan tr\u1ecdng:<\/strong><br \/> B\u00e1o c\u00e1o thu nh\u1eadp tr\u01b0\u1edbc \u0111\u00f3 v\u00e0o ng\u00e0y 6 th\u00e1ng 8 n\u0103m 2025 cho th\u1ea5y chi ti\u00eau R&amp;D t\u0103ng l\u00ean 54,7 tri\u1ec7u USD (t\u0103ng t\u1eeb 22,1 tri\u1ec7u USD n\u0103m 2024) v\u00e0 l\u1ed7 r\u00f2ng 61,7 tri\u1ec7u USD. M\u1eb7c d\u00f9 thua l\u1ed7, c\u00f4ng ty v\u1eabn duy tr\u00ec v\u1ecb th\u1ebf ti\u1ec1n m\u1eb7t m\u1ea1nh m\u1ebd 786,5 tri\u1ec7u USD, d\u1ef1 ki\u1ebfn s\u1ebd t\u00e0i tr\u1ee3 ho\u1ea1t \u0111\u1ed9ng \u0111\u1ebfn n\u0103m 2027 (<a href=\"https:\/\/www.stocktitan.net\/news\/GPCR\/structure-therapeutics-reports-second-quarter-2025-financial-results-lhkttczruz5p.html\">K\u1ebft qu\u1ea3 Q2 2025<\/a>).<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/vt\/register\/\" class=\"po-cta-green\">B\u1eaft \u0111\u1ea7u giao d\u1ecbch\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d Ph\u1ea3n \u1ee8ng Gi\u00e1 L\u1ecbch S\u1eed \u0110\u1ed1i V\u1edbi Tin L\u00e2m S\u00e0ng<\/h2>\n<p>C\u00e1c c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc nh\u01b0 GPCR th\u01b0\u1eddng tr\u1ea3i qua bi\u1ebfn \u0111\u1ed9ng gi\u00e1 \u0111\u00e1ng k\u1ec3 quanh c\u00e1c th\u00f4ng b\u00e1o th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 c\u00e1ch c\u1ed5 phi\u1ebfu \u0111\u00e3 ph\u1ea3n \u1ee9ng v\u1edbi c\u00e1c di\u1ec5n bi\u1ebfn g\u1ea7n \u0111\u00e2y:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ng\u00e0y<\/th>\n<th>S\u1ef1 ki\u1ec7n<\/th>\n<th>Thay \u0111\u1ed5i Gi\u00e1<\/th>\n<th>Th\u1eddi gian \u1ea2nh h\u01b0\u1edfng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Th\u00e1ng 8 2025<\/td>\n<td>C\u00f4ng b\u1ed1 Thu nh\u1eadp Q2<\/td>\n<td>-8% (tu\u1ea7n sau \u0111\u00f3)<\/td>\n<td>2 tu\u1ea7n<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 6 2025<\/td>\n<td>H\u1ed9i ngh\u1ecb Khoa h\u1ecdc ADA<\/td>\n<td>+12%<\/td>\n<td>3 ng\u00e0y<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 4 2025<\/td>\n<td>M\u1edf r\u1ed9ng Ch\u01b0\u01a1ng tr\u00ecnh L\u00e2m s\u00e0ng<\/td>\n<td>+15%<\/td>\n<td>1 tu\u1ea7n<\/td>\n<\/tr>\n<tr>\n<td>Th\u00e1ng 2 2025<\/td>\n<td>C\u1eadp nh\u1eadt Th\u1eed nghi\u1ec7m Giai \u0111o\u1ea1n 2<\/td>\n<td>+22%<\/td>\n<td>10 ng\u00e0y<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>M\u1eabu h\u00ecnh cho th\u1ea5y c\u00e1c ph\u00e1t tri\u1ec3n l\u00e2m s\u00e0ng t\u00edch c\u1ef1c th\u01b0\u1eddng th\u00fac \u0111\u1ea9y gi\u00e1 t\u0103ng ngay l\u1eadp t\u1ee9c, trong khi k\u1ebft qu\u1ea3 t\u00e0i ch\u00ednh g\u00e2y ra ph\u1ea3n \u1ee9ng th\u1eadn tr\u1ecdng h\u01a1n.<\/p>\n<h2>\ud83d\udcca Ph\u00e2n T\u00edch Hi\u1ec7u Su\u1ea5t Gi\u00e1 6 Th\u00e1ng<\/h2>\n<p>Structure Therapeutics \u0111\u00e3 tr\u1ea3i qua m\u1ed9t h\u00e0nh tr\u00ecnh kh\u00e1 bi\u1ebfn \u0111\u1ed9ng trong s\u00e1u th\u00e1ng qua:<\/p>\n<ul>\n<li><strong>Th\u00e1ng 2 n\u0103m 2025:<\/strong> C\u1ed5 phi\u1ebfu \u0111\u1ea1t \u0111\u1ec9nh 31,33 USD tr\u01b0\u1edbc khi gi\u1ea3m<\/li>\n<li><strong>Th\u00e1ng 3 n\u0103m 2025:<\/strong> Gi\u1ea3m xu\u1ed1ng 17,24 USD gi\u1eefa l\u00fac th\u1ecb tr\u01b0\u1eddng bi\u1ebfn \u0111\u1ed9ng<\/li>\n<li><strong>Th\u00e1ng 4 n\u0103m 2025:<\/strong> Ch\u1ea1m \u0111\u00e1y 13,22 USD r\u1ed3i ph\u1ee5c h\u1ed3i m\u1ea1nh m\u1ebd<\/li>\n<li><strong>Th\u00e1ng 5-6 n\u0103m 2025:<\/strong> \u1ed4n \u0111\u1ecbnh quanh v\u00f9ng 21-23 USD<\/li>\n<li><strong>Th\u00e1ng 7-8 n\u0103m 2025:<\/strong> Giao d\u1ecbch trong kho\u1ea3ng 18-20 USD v\u1edbi xu h\u01b0\u1edbng t\u0103ng g\u1ea7n \u0111\u00e2y<\/li>\n<\/ul>\n<p>Xu h\u01b0\u1edbng t\u1ed5ng th\u1ec3 cho th\u1ea5y <strong>s\u1ee5t gi\u1ea3m 35%<\/strong> t\u1eeb \u0111\u1ec9nh th\u00e1ng 2, nh\u01b0ng c\u1ed5 phi\u1ebfu \u0111\u00e3 th\u1ec3 hi\u1ec7n s\u1ef1 ki\u00ean c\u01b0\u1eddng v\u1edbi <strong>t\u0103ng 7,81%<\/strong> trong th\u00e1ng qua (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/structure-therapeutics-nasdaqgpcr-shares-gap-up-still-a-buy-2025-08-19\/\">Hi\u1ec7u su\u1ea5t G\u1ea7n \u0111\u00e2y<\/a>). Bi\u1ebfn \u0111\u1ed9ng n\u00e0y l\u00e0 \u0111i\u1ec3n h\u00ecnh cho c\u00e1c c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc giai \u0111o\u1ea1n l\u00e2m s\u00e0ng \u0111ang ch\u1edd d\u1eef li\u1ec7u quan tr\u1ecdng.<\/p>\n<h2>\ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: Tri\u1ec3n V\u1ecdng 2025-2030<\/h2>\n<p>D\u1ef1a tr\u00ean s\u1ef1 \u0111\u1ed3ng thu\u1eadn c\u1ee7a c\u00e1c nh\u00e0 ph\u00e2n t\u00edch v\u00e0 c\u00e1c m\u1ed1c l\u00e2m s\u00e0ng, \u0111\u00e2y l\u00e0 nh\u1eefng g\u00ec b\u1ea1n c\u00f3 th\u1ec3 mong \u0111\u1ee3i:<\/p>\n<ul>\n<li><strong>Cu\u1ed1i n\u0103m 2025:<\/strong> V\u00f9ng 50-75 USD (t\u00f9y thu\u1ed9c d\u1eef li\u1ec7u l\u00e2m s\u00e0ng)<\/li>\n<li><strong>D\u1ef1 b\u00e1o 2026:<\/strong> 75-90 USD (d\u1ef1 ki\u1ebfn b\u1eaft \u0111\u1ea7u Giai \u0111o\u1ea1n 3)<\/li>\n<li><strong>Tri\u1ec3n v\u1ecdng 2028:<\/strong> 120-150 USD (c\u00f3 th\u1ec3 n\u1ed9p h\u1ed3 s\u01a1 ph\u00ea duy\u1ec7t)<\/li>\n<li><strong>T\u1ea7m nh\u00ecn 2030:<\/strong> Tr\u00ean 200 USD (giai \u0111o\u1ea1n th\u01b0\u01a1ng m\u1ea1i h\u00f3a)<\/li>\n<\/ul>\n<p>M\u1ee5c ti\u00eau gi\u00e1 trung b\u00ecnh c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch l\u00e0 <strong>75,63 USD<\/strong>, t\u01b0\u01a1ng \u0111\u01b0\u01a1ng <strong>ti\u1ec1m n\u0103ng t\u0103ng 285%<\/strong> so v\u1edbi m\u1ee9c hi\u1ec7n t\u1ea1i (<a href=\"https:\/\/stockanalysis.com\/stocks\/gpcr\/forecast\/\">\u0110\u1ed3ng thu\u1eadn Nh\u00e0 ph\u00e2n t\u00edch<\/a>). H\u1ea7u h\u1ebft c\u00e1c nh\u00e0 ph\u00e2n t\u00edch duy tr\u00ec \u0111\u00e1nh gi\u00e1 &#8220;Mua M\u1ea1nh&#8221; v\u1edbi ch\u1ec9 c\u00e1c khuy\u1ebfn ngh\u1ecb t\u00edch c\u1ef1c.<\/p>\n<p><strong>K\u1ebft lu\u1eadn: MUA<\/strong> &#8211; T\u1ef7 l\u1ec7 r\u1ee7i ro-l\u1ee3i nhu\u1eadn \u1ee7ng h\u1ed9 \u0111\u1ea7u t\u01b0, \u0111\u1eb7c bi\u1ec7t tr\u01b0\u1edbc c\u00e1c d\u1eef li\u1ec7u l\u00e2m s\u00e0ng quan tr\u1ecdng.<\/p>\n<h2>\u26a0\ufe0f R\u1ee7i Ro \u0110\u1ea7u T\u01b0 C\u1ea7n L\u01b0u \u00dd<\/h2>\n<p>Tr\u01b0\u1edbc khi \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR), h\u00e3y hi\u1ec3u c\u00e1c r\u1ee7i ro sau:<\/p>\n<ul>\n<li><strong>Th\u1ea5t b\u1ea1i Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng:<\/strong> Thu\u1ed1c ch\u1ee7 l\u1ef1c aleniglipron c\u00f3 th\u1ec3 th\u1ea5t b\u1ea1i \u1edf Giai \u0111o\u1ea1n 2 ho\u1eb7c 3<\/li>\n<li><strong>R\u00e0o c\u1ea3n Ph\u00e1p l\u00fd:<\/strong> FDA kh\u00f4ng bao gi\u1edd \u0111\u1ea3m b\u1ea3o ph\u00ea duy\u1ec7t thu\u1ed1c m\u1edbi<\/li>\n<li><strong>C\u1ea1nh tranh:<\/strong> C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn \u0111ang ph\u00e1t tri\u1ec3n thu\u1ed1c GLP-1 \u0111\u01b0\u1eddng u\u1ed1ng t\u01b0\u01a1ng t\u1ef1<\/li>\n<li><strong>Ti\u00eau ti\u1ec1n M\u1ea1nh:<\/strong> L\u1ed7 61,7 tri\u1ec7u USD m\u1ed7i qu\u00fd \u0111\u00f2i h\u1ecfi qu\u1ea3n l\u00fd v\u1ed1n c\u1ea9n th\u1eadn<\/li>\n<li><strong>Bi\u1ebfn \u0111\u1ed9ng Th\u1ecb tr\u01b0\u1eddng:<\/strong> C\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc c\u00f3 th\u1ec3 dao \u0111\u1ed9ng tr\u00ean 20% ch\u1ec9 v\u1edbi m\u1ed9t tin t\u1ee9c<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c Cho \u0110\u1ea7u T\u01b0 2025<\/h2>\n<p>B\u1ea5t ch\u1ea5p r\u1ee7i ro, c\u00f3 nhi\u1ec1u y\u1ebfu t\u1ed1 h\u1ed7 tr\u1ee3 \u0111\u1ea7u t\u01b0:<\/p>\n<ul>\n<li><strong>\u0110\u1ec7m Ti\u1ec1n M\u1eb7t 786,5 Tri\u1ec7u USD:<\/strong> T\u00e0i tr\u1ee3 ho\u1ea1t \u0111\u1ed9ng \u0111\u1ebfn n\u0103m 2027 m\u00e0 kh\u00f4ng pha lo\u00e3ng c\u1ed5 ph\u1ea7n<\/li>\n<li><strong>L\u1ee3i Th\u1ebf Thu\u1ed1c \u0110\u01b0\u1eddng U\u1ed1ng:<\/strong> Ti\u1ec1m n\u0103ng thay \u0111\u1ed5i cu\u1ed9c ch\u01a1i so v\u1edbi thu\u1ed1c ti\u00eam<\/li>\n<li><strong>M\u1edf R\u1ed9ng Danh M\u1ee5c:<\/strong> Ba nghi\u00ean c\u1ee9u l\u00e2m s\u00e0ng m\u1edbi n\u00e2ng cao v\u1ecb th\u1ebf c\u1ea1nh tranh<\/li>\n<li><strong>H\u1ed7 Tr\u1ee3 Nh\u00e0 Ph\u00e2n T\u00edch:<\/strong> 95% khuy\u1ebfn ngh\u1ecb mua v\u1edbi m\u1ee5c ti\u00eau gi\u00e1 cao<\/li>\n<li><strong>Th\u1eddi \u0110i\u1ec3m Th\u1ecb Tr\u01b0\u1eddng:<\/strong> D\u1eef li\u1ec7u quan tr\u1ecdng d\u1ef1 ki\u1ebfn cu\u1ed1i n\u0103m 2025 c\u00f3 th\u1ec3 k\u00edch ho\u1ea1t t\u0103ng tr\u01b0\u1edfng<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Nh\u00e0 Giao D\u1ecbch M\u1edbi N\u00ean L\u00e0m G\u00ec H\u00f4m Nay?<\/h2>\n<ol>\n<li><strong>B\u1eaft \u0110\u1ea7u Nh\u1ecf:<\/strong> Ch\u1ec9 ph\u00e2n b\u1ed5 2-5% danh m\u1ee5c cho c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc r\u1ee7i ro cao<\/li>\n<li><strong>Trung B\u00ecnh Gi\u00e1:<\/strong> Mua theo t\u1eebng ph\u1ea7n thay v\u00ec m\u1ed9t l\u1ea7n<\/li>\n<li><strong>\u0110\u1eb7t C\u1ea3nh B\u00e1o Gi\u00e1:<\/strong> Theo d\u00f5i khi gi\u00e1 gi\u1ea3m d\u01b0\u1edbi 18 USD \u0111\u1ec3 c\u00f3 \u0111i\u1ec3m v\u00e0o t\u1ed1t h\u01a1n<\/li>\n<li><strong>Chu\u1ea9n B\u1ecb Cho Bi\u1ebfn \u0110\u1ed9ng:<\/strong> C\u00f3 k\u1ebf ho\u1ea1ch cho c\u1ea3 tin t\u00edch c\u1ef1c v\u00e0 ti\u00eau c\u1ef1c<\/li>\n<li><strong>Ki\u1ec3m Tra Th\u1ef1c T\u1ebf H\u00e0i H\u01b0\u1edbc:<\/strong> &#8220;Giao d\u1ecbch c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2 &#8211; th\u00fa v\u1ecb cho \u0111\u1ebfn khi k\u1ebft qu\u1ea3 Giai \u0111o\u1ea1n 3 ra. Lu\u00f4n c\u00f3 chi\u1ebfn l\u01b0\u1ee3c tho\u00e1t!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Structure Therapeutics Inc. (GPCR) &#8211; T\u1eebng B\u01b0\u1edbc<\/h2>\n<table>\n<thead>\n<tr>\n<th>B\u01b0\u1edbc<\/th>\n<th>H\u00e0nh \u0110\u1ed9ng<\/th>\n<th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ch\u1ecdn N\u1ec1n T\u1ea3ng Giao D\u1ecbch<\/td>\n<td>\u0110\u1ea3m b\u1ea3o n\u1ec1n t\u1ea3ng cung c\u1ea5p c\u1ed5 phi\u1ebfu ni\u00eam y\u1ebft tr\u00ean NASDAQ<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Ho\u00e0n Th\u00e0nh N\u1ea1p Ti\u1ec1n T\u00e0i Kho\u1ea3n<\/td>\n<td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u00f3 th\u1ec3 ch\u1ea5p nh\u1eadn r\u1ee7i ro<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>T\u00ecm ki\u1ebfm &#8220;GPCR&#8221;<\/td>\n<td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n, kh\u00f4ng ph\u1ea3i t\u00ean c\u00f4ng ty<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Ch\u1ecdn Lo\u1ea1i L\u1ec7nh<\/td>\n<td>D\u00f9ng l\u1ec7nh gi\u1edbi h\u1ea1n \u0111\u1ec3 ki\u1ec3m so\u00e1t gi\u00e1 v\u00e0o<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Xem L\u1ea1i v\u00e0 X\u00e1c Nh\u1eadn<\/td>\n<td>Ki\u1ec3m tra ph\u00ed hoa h\u1ed3ng tr\u01b0\u1edbc khi th\u1ef1c hi\u1ec7n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 T\u1ea1i Sao Pocket Option Thu H\u00fat Nh\u00e0 \u0110\u1ea7u T\u01b0 M\u1edbi<\/h2>\n<p>\u0110\u1ed1i v\u1edbi nh\u1eefng ai \u0111ang c\u00e2n nh\u1eafc c\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR), Pocket Option mang l\u1ea1i nhi\u1ec1u l\u1ee3i th\u1ebf:<\/p>\n<ul>\n<li><strong>Ti\u1ec1n N\u1ea1p T\u1ed1i Thi\u1ec3u:<\/strong> Ch\u1ec9 5 USD \u0111\u1ec3 b\u1eaft \u0111\u1ea7u giao d\u1ecbch<\/li>\n<li><strong>X\u00e1c Minh Nhanh:<\/strong> KYC ho\u00e0n th\u00e0nh ch\u1ec9 v\u1edbi m\u1ed9t t\u00e0i li\u1ec7u t\u1ea3i l\u00ean<\/li>\n<li><strong>Nhi\u1ec1u Ph\u01b0\u01a1ng Th\u1ee9c R\u00fat Ti\u1ec1n:<\/strong> H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c bao g\u1ed3m c\u1ea3 ti\u1ec1n \u0111i\u1ec7n t\u1eed<\/li>\n<li><strong>N\u1ec1n T\u1ea3ng Th\u00e2n Thi\u1ec7n Ng\u01b0\u1eddi D\u00f9ng:<\/strong> L\u00fd t\u01b0\u1edfng cho ng\u01b0\u1eddi m\u1edbi h\u1ecdc giao d\u1ecbch c\u1ed5 phi\u1ebfu<\/li>\n<li><strong>T\u00e0i Nguy\u00ean Gi\u00e1o D\u1ee5c:<\/strong> Truy c\u1eadp ph\u00e2n t\u00edch th\u1ecb tr\u01b0\u1eddng v\u00e0 c\u00f4ng c\u1ee5 giao d\u1ecbch<\/li>\n<\/ul>\n<h2>\ud83e\uddec Structure Therapeutics N\u0103m 2025: Nh\u00e0 \u0110\u1ed5i M\u1edbi C\u00f4ng Ngh\u1ec7 Sinh H\u1ecdc<\/h2>\n<p>Structure Therapeutics Inc. l\u00e0 c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng \u0111\u01b0\u1ee3c th\u00e0nh l\u1eadp n\u0103m 2016 v\u00e0 c\u00f3 tr\u1ee5 s\u1edf t\u1ea1i South San Francisco. C\u00f4ng ty chuy\u00ean ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p ph\u00e2n t\u1eed nh\u1ecf \u0111\u01b0\u1eddng u\u1ed1ng nh\u1eafm v\u00e0o c\u00e1c th\u1ee5 th\u1ec3 li\u00ean k\u1ebft protein G (GPCR) cho c\u00e1c b\u1ec7nh chuy\u1ec3n h\u00f3a v\u00e0 tim ph\u1ed5i.<\/p>\n<p>\u1ee8ng vi\u00ean ch\u1ee7 l\u1ef1c <strong>aleniglipron<\/strong> (GSBR-1290) l\u00e0 ch\u1ea5t ch\u1ee7 v\u1eadn th\u1ee5 th\u1ec3 GLP-1 \u0111\u01b0\u1eddng u\u1ed1ng \u0111ang trong th\u1eed nghi\u1ec7m Giai \u0111o\u1ea1n 2b \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb b\u00e9o ph\u00ec. C\u00f4ng ty g\u1ea7n \u0111\u00e2y \u0111\u00e3 ho\u00e0n th\u00e0nh tuy\u1ec3n d\u1ee5ng cho c\u00e1c nghi\u00ean c\u1ee9u ACCESS v\u00e0 ACCESS II, v\u1edbi d\u1eef li\u1ec7u t\u1ed5ng quan d\u1ef1 ki\u1ebfn v\u00e0o cu\u1ed1i n\u0103m 2025 (<a href=\"https:\/\/trial.medpath.com\/news\/f4f0d98090a52484\/structure-therapeutics-advances-oral-obesity-drug-programs-with-completed-enrollment-in-key-aleniglipron-trials\">C\u1eadp nh\u1eadt Th\u1eed nghi\u1ec7m L\u00e2m s\u00e0ng<\/a>).<\/p>\n<p><strong>S\u1ef1 ki\u1ec7n th\u00fa v\u1ecb n\u0103m 2025:<\/strong> Structure Therapeutics \u0111\u00e3 g\u00e2y ch\u00fa \u00fd t\u1ea1i H\u1ed9i ngh\u1ecb Khoa h\u1ecdc l\u1ea7n th\u1ee9 85 c\u1ee7a Hi\u1ec7p h\u1ed9i \u0110\u00e1i th\u00e1o \u0111\u01b0\u1eddng Hoa K\u1ef3 v\u1edbi nghi\u00ean c\u1ee9u \u0111\u1ed9t ph\u00e1 cho th\u1ea5y li\u1ec7u ph\u00e1p \u0111\u01b0\u1eddng u\u1ed1ng c\u1ee7a h\u1ecd c\u00f3 th\u1ec3 lo\u1ea1i b\u1ecf n\u1ed7i s\u1ee3 kim ti\u00eam cho h\u00e0ng tri\u1ec7u b\u1ec7nh nh\u00e2n ti\u1ec3u \u0111\u01b0\u1eddng v\u00e0 b\u00e9o ph\u00ec tr\u00ean to\u00e0n th\u1ebf gi\u1edbi!<\/p>\n"},"faq":[{"question":"Structure Therapeutics Inc. (GPCR) l\u00e0 c\u00f4ng ty g\u00ec?","answer":"Structure Therapeutics Inc. l\u00e0 c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng chuy\u00ean ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p ph\u00e2n t\u1eed nh\u1ecf \u0111\u01b0\u1eddng u\u1ed1ng nh\u1eafm v\u00e0o c\u00e1c th\u1ee5 th\u1ec3 li\u00ean k\u1ebft protein G (GPCR) \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh chuy\u1ec3n h\u00f3a v\u00e0 tim ph\u1ed5i."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu GPCR?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu GPCR th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch cung c\u1ea5p c\u1ed5 phi\u1ebfu ni\u00eam y\u1ebft tr\u00ean NASDAQ, t\u00ecm m\u00e3 \"GPCR\", ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 x\u00e1c nh\u1eadn giao d\u1ecbch sau khi n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n."},{"question":"R\u1ee7i ro khi \u0111\u1ea7u t\u01b0 v\u00e0o Structure Therapeutics l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro bao g\u1ed3m th\u1ea5t b\u1ea1i trong th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng, r\u00e0o c\u1ea3n ph\u00e1p l\u00fd t\u1eeb FDA, c\u1ea1nh tranh t\u1eeb c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn, ti\u00eau ti\u1ec1n m\u1ea1nh v\u00e0 bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng cao."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu GPCR trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu GPCR c\u00f3 th\u1ec3 \u0111\u1ea1t t\u1eeb 50-75 USD v\u00e0o cu\u1ed1i n\u0103m 2025, t\u0103ng l\u00ean 75-90 USD n\u0103m 2026, 120-150 USD n\u0103m 2028 v\u00e0 tr\u00ean 200 USD v\u00e0o n\u0103m 2030 t\u00f9y thu\u1ed9c v\u00e0o ti\u1ebfn tri\u1ec3n l\u00e2m s\u00e0ng v\u00e0 ph\u00ea duy\u1ec7t."},{"question":"T\u1ea1i sao n\u00ean \u0111\u1ea7u t\u01b0 v\u00e0o Structure Therapeutics n\u0103m 2025?","answer":"C\u00f4ng ty c\u00f3 \u0111\u1ec7m ti\u1ec1n m\u1eb7t l\u1edbn, l\u1ee3i th\u1ebf thu\u1ed1c \u0111\u01b0\u1eddng u\u1ed1ng, danh m\u1ee5c nghi\u00ean c\u1ee9u m\u1edf r\u1ed9ng, s\u1ef1 h\u1ed7 tr\u1ee3 m\u1ea1nh m\u1ebd t\u1eeb nh\u00e0 ph\u00e2n t\u00edch v\u00e0 th\u1eddi \u0111i\u1ec3m th\u1ecb tr\u01b0\u1eddng thu\u1eadn l\u1ee3i v\u1edbi d\u1eef li\u1ec7u quan tr\u1ecdng d\u1ef1 ki\u1ebfn cu\u1ed1i n\u0103m 2025."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Structure Therapeutics Inc. (GPCR) l\u00e0 c\u00f4ng ty g\u00ec?","answer":"Structure Therapeutics Inc. l\u00e0 c\u00f4ng ty d\u01b0\u1ee3c ph\u1ea9m giai \u0111o\u1ea1n l\u00e2m s\u00e0ng chuy\u00ean ph\u00e1t tri\u1ec3n c\u00e1c li\u1ec7u ph\u00e1p ph\u00e2n t\u1eed nh\u1ecf \u0111\u01b0\u1eddng u\u1ed1ng nh\u1eafm v\u00e0o c\u00e1c th\u1ee5 th\u1ec3 li\u00ean k\u1ebft protein G (GPCR) \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb c\u00e1c b\u1ec7nh chuy\u1ec3n h\u00f3a v\u00e0 tim ph\u1ed5i."},{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 mua c\u1ed5 phi\u1ebfu GPCR?","answer":"B\u1ea1n c\u00f3 th\u1ec3 mua c\u1ed5 phi\u1ebfu GPCR th\u00f4ng qua c\u00e1c n\u1ec1n t\u1ea3ng giao d\u1ecbch cung c\u1ea5p c\u1ed5 phi\u1ebfu ni\u00eam y\u1ebft tr\u00ean NASDAQ, t\u00ecm m\u00e3 \"GPCR\", ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 x\u00e1c nh\u1eadn giao d\u1ecbch sau khi n\u1ea1p ti\u1ec1n v\u00e0o t\u00e0i kho\u1ea3n."},{"question":"R\u1ee7i ro khi \u0111\u1ea7u t\u01b0 v\u00e0o Structure Therapeutics l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro bao g\u1ed3m th\u1ea5t b\u1ea1i trong th\u1eed nghi\u1ec7m l\u00e2m s\u00e0ng, r\u00e0o c\u1ea3n ph\u00e1p l\u00fd t\u1eeb FDA, c\u1ea1nh tranh t\u1eeb c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn, ti\u00eau ti\u1ec1n m\u1ea1nh v\u00e0 bi\u1ebfn \u0111\u1ed9ng th\u1ecb tr\u01b0\u1eddng cao."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu GPCR trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu GPCR c\u00f3 th\u1ec3 \u0111\u1ea1t t\u1eeb 50-75 USD v\u00e0o cu\u1ed1i n\u0103m 2025, t\u0103ng l\u00ean 75-90 USD n\u0103m 2026, 120-150 USD n\u0103m 2028 v\u00e0 tr\u00ean 200 USD v\u00e0o n\u0103m 2030 t\u00f9y thu\u1ed9c v\u00e0o ti\u1ebfn tri\u1ec3n l\u00e2m s\u00e0ng v\u00e0 ph\u00ea duy\u1ec7t."},{"question":"T\u1ea1i sao n\u00ean \u0111\u1ea7u t\u01b0 v\u00e0o Structure Therapeutics n\u0103m 2025?","answer":"C\u00f4ng ty c\u00f3 \u0111\u1ec7m ti\u1ec1n m\u1eb7t l\u1edbn, l\u1ee3i th\u1ebf thu\u1ed1c \u0111\u01b0\u1eddng u\u1ed1ng, danh m\u1ee5c nghi\u00ean c\u1ee9u m\u1edf r\u1ed9ng, s\u1ef1 h\u1ed7 tr\u1ee3 m\u1ea1nh m\u1ebd t\u1eeb nh\u00e0 ph\u00e2n t\u00edch v\u00e0 th\u1eddi \u0111i\u1ec3m th\u1ecb tr\u01b0\u1eddng thu\u1eadn l\u1ee3i v\u1edbi d\u1eef li\u1ec7u quan tr\u1ecdng d\u1ef1 ki\u1ebfn cu\u1ed1i n\u0103m 2025."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T09:05:39+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)\",\"datePublished\":\"2025-08-25T09:05:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/\"},\"wordCount\":23,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-25T09:05:39+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T09:05:39+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)","datePublished":"2025-08-25T09:05:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/"},"wordCount":23,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-25T09:05:39+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-structure-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR) &#8211; \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Structure Therapeutics Inc. (GPCR)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":345916,"slug":"how-to-buy-structure-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Structure Therapeutics Inc. (GPCR) - Investimento em a\u00e7\u00f5es da Structure Therapeutics Inc. (GPCR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-structure-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/345913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=345913"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/345913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=345913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=345913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=345913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}